P6‐44: Case report of a newly diagnosed bacteriologically confirmed pulmonary tuberculosis in a patient with COVID‐19 critical infection

Upon administration of the anti-TB medications, baseline laboratory work-up done revealed hyperuricemia in 28.3% patients.The study showed the distribution of occurrence of gouty arthritis attacks during the 1st and 2nd month intensive phase and 1st month continuation phase.11 patients with baseline gout have experienced gout attacks while 16 patients without baseline gouty arthritis experienced gout attacks during the 1st month of intensive treatment.Ten patients with baseline gout and four patients without baseline gouty arthritis experienced gout attacks during the 2nd month of intensive treatment.Further decrease of gout attacks was observed on the 1st month continuation phase.The indicators resulting to gouty arthritis attacks were hypertension, dyslipidemia, azotemia and hyperuricemia.Among patients who had gouty attacks, 33.4% went into resolution with medications and 1.67% patient was hospitalized. Conclusion:The main adverse effects of anti-TB drugs can be alleviated with drugs that control uric acid and anti-gout agents.The prompt administration of these drugs and correct lifestyle made possible to continue the anti-tuberculous therapy without withdrawing anti-TB medications.The timely strict monitoring and management of adverse effects including patient education, clinical examination, and serial laboratory tests are essential.If these side effects are not recognized in time and managed properly they can lead to treatment interruption of therapy or even life threatening complications.Furthermore, Patient's tolerance of antituberculosis drugs is important for the treatment outcomes and as a consequence for tuberculosis control in general.